Did you know?

For all those that accuse Mike of not getting enough done, based on what I have seen Mike has many many irons in the fire. Building MannKind's own Scientific Advisory Board is pretty cool. Looks like some pretty good names in this group. What a great idea.MannKind MNKD Message Board. All About MNKD. BIOMM WILL START DISTRIBUTION OF AFREZZA. MannKind. All About MNKD. MNKD Product Script Counts and Other Metrics. Articles. MNKD Resource Center. Off Topic. Other BioPharma Stocks. Other Stocks. Markets and Media. Trading and Investing Strategies. Really Off Topic.Message board for discussion of MNKD, MannKind Corporation. That post prandial control goes first has been known for a long time (decades) which is why you have the OGTT, Oral Glucose tolerance test, as part of the diagnosis for Type 2.Message board for discussion of MNKD, MannKind Corporation. Mannkind just posted this on facebook: This weekend we look to Saarbrücken, Germany, where the International Society for Aerosols in Medicine (ISAM) 2023 Congress gets underway.They are also building a large $60 million expansion in Danbury right now. Right now Tyvaso is a little over $300 million/qtr ($30 million per week). So if the product ships on a Thursday instead of a Monday, that could change the $30 million, so I wouldn't read too much into that $30 million is my whole point.Message board for discussion of MNKD, MannKind Corporation. Here's the Mannkind bio from the corporate web page below. Graduated in 1985, 16 years with one company, 19 with another, timeline fits. 60-65 age range fits.I think "the point" was that parrerob provided an excellent estimate well in advance of the Wall Street analysts. It was a compliment to both parrerob and Mannkind. BD. Administrator. Posts: 3,681. FY 2023 Forecast. Jul 14, 2023 at 4:44am cretin11 likes this. Reply Quote.Clearly MNKD would not need the Tyvaso DPI revenue to pay the bills. As far as Mike giving up on the T2 market thats not really the case. Mike has been trying to figure out how to return the $3B+ the shareholders have invested in afrezza with limited cash and without taking risks which could bankrupt the company. Mike, himself is a T2.Message board for discussion of MNKD, MannKind Corporation. Then there is this, "The Company's V-Go is the first FDA-approved product that utilizes the h-Patch™ technology.Message board for discussion of MNKD, MannKind Corporation. Upgrade to SP target by BTIG might be contributing, but there were also adds by institutions in the 3rd and 4th quarters, so not unreasonable to assume more of the same plus an uptick in retail purchases.Message board for discussion of MNKD, MannKind Corporation. DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael ...MannKind MNKD Message Board. All About MNKD. What about TS GLP-1? MannKind. All About MNKD. MNKD Product Script Counts and Other Metrics. Articles. MNKD Resource Center. Off Topic. Other BioPharma Stocks. Other Stocks. Markets and Media. Trading and Investing Strategies. Really Off Topic. The Lighter Side. Documents and User Tips.To approve an amendment to the MannKind 2004 Employee Stock Purchase Plan (the “ESPP”) to increase the number of shares authorized for issuance thereunder by 3,000,000 shares; 6. To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind’s proxy statement for the Annual Meeting; 7.MannKind MNKD Message Board. All About MNKD. MannKind Renegotiates Near-Term Maturities with Deerfield. MannKind. All About MNKD. MNKD Product Script Counts and Other Metrics. Articles. MNKD Resource Center. Off Topic. Other BioPharma Stocks. Other Stocks. Markets and Media. Trading and Investing Strategies.

Not sure we have the personnel in place to accomplish it, which leads to sayhey24's point that MNKD needs a serious partner for it. After years of having no more success selling Afrezza than Sisyphus pushing his rock up the hill, that point seems clear now too! mango. Postaholic. Posts: 5,729. ADA 2023.This article is essentially a predictor for Mannkind's earnings report Monday morning. Obviously this is a bit speculative, but I will also look at the big picture for the company, and point to recent developments in an attempt to explain that Mannkind (NASDAQ:MNKD) is saving a treat for investors. Let's begin. DevelopmentsHere since 2011 Lost too much money believing in Al Mann (but I still believe) But now I’m here for my diehards who still believe!! Thank you to the Peppy’s and joey’s of the world with the charMessage board for discussion of MNKD, MannKind Corporation." I think that 49% ratio between DPI and old Tyvaso is quite conservative. "increase in quantities sold to our domestic distributors of $112.0 million. $96.9 million of this growth resulted from an increased number of patients following the commercial launch of Tyvaso DPI in June 2022" that's quite a lot compared to 318,9 total ...

The 400M share authorization request mentioned defense against a hostile take-over. Keep your friends close, and your enemies closer. agedhippie. Postaholic. Posts: 5,478. Sentiment: On the Sidelines. Reason for the Authorized Share increase to 800M. May 10, 2023 at 3:00pm Chris-C, prcgorman2, and 3 more like this.Post text articles and multimedia spots about MNKD/Afrezza here. No New Posts, MNKD Resource Center. A collection of links etc for the MNKD investor.DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Message board for discussion of MNKD, MannKind Corporation. I love r. Possible cause: 1Q 2023 Revenues associated with Tyvaso DPI of $23 million. 1Q 2023 Loss from operation.